Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors

NCT06541262 is registered in ClinicalTrials.gov with Milton S. Hershey Medical Center as lead sponsor.

NCT NCT06541262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06541262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors
Lead sponsor
Milton S. Hershey Medical Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 30, 2024
Completion date
November 1, 2035
Enrollment
104 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, liposarcoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma